Skip to content
Sign in
StableHealthReported 2026-11-19 11:45

AstraZeneca Secures FDA Approval for Imfinzi Combo in MIBC

AstraZeneca received FDA approval for Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for treating muscle-invasive bladder cancer (MIBC).

Why it matters. AstraZeneca's approval offers a novel regimen that reduces the risk of disease progression and death in MIBC, benefiting patients who cannot tolerate cisplatin-based chemotherapy.

01

Evidence

  • GGDELT Global Knowledge GraphMedia2026-11-19 11:45
    View source